NF1 and neurofibromatosis: The primary reason cited explicitly by oncologists in their clinical notes for their choice to use a novel drug was genomic results identified through molecular diagnostics or inferred based on clinical diagnosis in the case of NF1 in neurofibromatosis (N = 44, 33.1%) (Table S1).